Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 256 full-time employees. The company went IPO on 2022-09-23. The company is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Follow-Up Questions
Who is the CEO of Biohaven Ltd?
Dr. Vlad Coric is the Chairman of the Board of Biohaven Ltd, joining the firm since 2015.
What is the price performance of BHVN stock?
The current price of BHVN is $14.04, it has increased 0.68% in the last trading day.
What are the primary business themes or industries for Biohaven Ltd?
Biohaven Ltd belongs to Biotechnology industry and the sector is Health Care
What is Biohaven Ltd market cap?
Biohaven Ltd's current market cap is $1.4B
Is Biohaven Ltd a buy, sell, or hold?
According to wall street analysts, 18 analysts have made analyst ratings for Biohaven Ltd, including 9 strong buy, 11 buy, 2 hold, 0 sell, and 9 strong sell
